SCHEMBL3759227

SCHEMBL3759227

Cc1c(-c2ccccc2)[c]nc(NC(=O)OC(C)(C)C)c1C(=O)N1CCC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KMT2A Q03164 3/20 0.39
CKS1B P61024 3/20 0.39
SKP1 P63208 3/20 0.39
SKP2 Q13309 3/20 0.39
BRD9 Q9H8M2 1/20 0.38
MEN1 O00255 2/20 0.36
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
OGFRL1 Q5TC84 1/20 0.35
BCL2 P10415 3/20 0.35
BECN1 Q14457 2/20 0.35
HPGD P15428 1/20 0.34
ABL1 P00519 1/20 0.34
RIN1 Q13671 1/20 0.34
MAPT P10636 1/20 0.34
KIT P10721 1/20 0.34
USP30 Q70CQ3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3756638 0.98 KMT2A (0.41) HTTSMN1; SMN2KMT2ACKS1BSKP1
SCHEMBL4004236 0.80 SMN1; SMN2 (0.46) HTTSMN1; SMN2KMT2AMEN1HPGD
SCHEMBL4003843 0.80 KMT2A (0.46) HTTSMN1; SMN2KMT2AMEN1HPGD
SCHEMBL3767247 0.79 CKS1B (0.41) HTTSMN1; SMN2KMT2ACKS1BSKP1
SCHEMBL3755044 0.77 BRD9 (0.40) HTTSMN1; SMN2KMT2ACKS1BSKP1
SCHEMBL3759007 0.76 HTT (0.48) HTTSMN1; SMN2KMT2AMEN1HPGD
SCHEMBL3766617 0.76 BRD9 (0.40) HTTSMN1; SMN2KMT2ACKS1BSKP1
SCHEMBL3759817 0.75 LMNA (0.36) KMT2A
SCHEMBL3761663 0.74 KMT2A (0.49) HTTSMN1; SMN2KMT2AMEN1HPGD
SCHEMBL3764873 0.69 BRD9 (0.47) KMT2ACKS1BSKP1SKP2BRD9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA HTT 1234/4885SMN1; SMN2 1864/4885KMT2A 2175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.